Recap of Key U.S. Biotechnology and Pharmaceutical Sector Events: October 17
Celgene (NASDAQ: CELG) announced successful phase 1b data of its antisense therapy GED-0301 in the treatment of Crohn's disease (48% remission rate...
216 Views
The Chickens Are Ready to Roost
Several recent developments confirm our thesis that Inflectra's US sales in 2017 will fall far short of management's 2017 forecast. First, Pfizer's...
203 Views
Teva May Buy Celltrion - Implications for Celltrion & Celltrion Healthcare
How should we interpret Teva's potential acquisition of Celltrion? Is this for real? Well, Teva may still be very interested in acquiring Celltrion...
211 Views
Strike 2 in St Louis: Trump's Town Hall Trap
Before the Battle. Even before this key 2nd presidential debate in St Louis on October 9 (but October 10 Thai time), the press raised many issues....
208 Views
More Harsh Reality from Teva
U.S. healthcare industry leaders from across the spectrum of industry segments continue to downplay the near-term adoption of biosimilars in the...
199 Views